The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib
FUTURE ONCOLOGY, cilt.18, ss.1067-1076, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18
- Basım Tarihi: 2022
- Doi Numarası: 10.2217/fon-2021-1182
- Dergi Adı: FUTURE ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.1067-1076
- Anahtar Kelimeler: colon cancer, drug interaction, rectal cancer, regorafenib, COMPREHENSIVE GERIATRIC ASSESSMENT, POTENTIAL-DRUG INTERACTIONS, PALLIATIVE CARE, ELDERLY-PATIENTS, RISK-FACTORS, CHEMOTHERAPY, SURVIVAL, MEDICATIONS
- Ankara Üniversitesi Adresli: Evet
Özet
Aim: To evaluate polypharmacy (PP) in patients with metastatic colorectal cancer receiving regorafenib. Methods: Patients with metastatic colorectal cancer receiving regorafenib were included and divided into two categories by their PP status: PP- (<5 regular drug use/day) and PP+ (>= 5 regular drug use/day). Results: 80 patients were included. 31 (38.7%) patients had PP. The median number of drugs used was three and seven in PP- and PP+ patients, respectively. Antiemetics (26.5%) and antacids (48.4%) were the most common drugs used by PP- and PP+ patients, respectively. In multivariate analysis, the risk of death was higher in PP+ patients (hazard ratio: 2.1; 95% CI: 1.2-3.7; p = 0.005). Conclusion: PP was an independent prognostic factor for overall survival in patients with metastatic colorectal cancer receiving regorafenib.